SARS-CoV-2 is a novel virus which emerged in Wuhan, China in late 2019. SARS-CoV-2 was declared a pandemic by the World Health Organisation (WHO) on 11 March. SARS-CoV-2 is sufficiently divergent from SARS-CoV which emerged in 2003 to be considered a novel virus.
Aalto Bio Reagents is developing a range SARS-CoV-2 products for diagnostic test manufacturers, vaccine developers and researchers globally. Check back regularly to see the product range or contact us to sign up for regular updates on new coronavirus products.
SARS-CoV-2 Structural Proteins
SARS-CoV-2 virus particles consist of 4 or 5 structural proteins including the nucleocapsid (N), Spike (S), Envelope (E) and membrane (M). Previous studies have identified these SARS-CoV-2 structural proteins as excellent candidates for diagnostics antigens in other highly similar viruses.
The nucleocapsid protein plays a fundamental role during virion assembly through its interactions with the viral genome and membrane protein M. It also has an essential role in enhancing the efficiency of subgenomic viral RNA transcription as well as viral replication.
Aalto Bio Reagents supplies a recombinant SARS-CoV-2 nucleocapsid protein derived from both insect cell (BM 6424) and E. coli (CK 6404-b) for diagnostic test manufacturers, vaccine developers and researchers globally.
The Spike protein is a large class I fusion protein which mediates the fusion process between viral and host membranes. The Spike protein consists of two subunits S1 and S2 with the N terminal S1 providing receptor binding function and S2 at the C terminal providing fusion activity. Sequence analysis has shown a closer relationship between the S1 domain of SARS-CoV-2 and SARS-CoV that is observable at a whole genome level. This suggests that like SARS-CoV, SARS-CoV-2 may also use angiotensin-converting enzyme 2 (ACE2) as a cell receptor.
Contact our sales team at email@example.com to discuss your requirements.